Chronic exposure to manganese decreases striatal dopamine turnover in human alpha-synuclein transgenic mice

Neuroscience

Volumn 180, Issue , 2011, Pages 280-292

  Peneder, T M ^a   Scholze, P ^a   Berger, M L ^a   Reither, H ^a   Heinze, G ^b   Bertl, J ^b   Bauer, J ^a   Richfield, E K ^c   Hornykiewicz, O ^a   Pifl, C ^a  

^a Medical University of Vienna   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

synuclein; Amino acids; Dopamine; Dopamine turnover; Manganese; Transgene

Indexed keywords

ALPHA SYNUCLEIN; ASPARTIC ACID; DOPAMINE; HOMOVANILLIC ACID; MANGANESE; MANGANESE CHLORIDE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; CORPUS STRIATUM; DEGENERATIVE DISEASE; DOPAMINE METABOLISM; LOCOMOTION; MALE; MOUSE; NERVE CELL; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN SECRETION; SUBSTANTIA NIGRA PARS COMPACTA; TRANSGENE; TRANSGENIC MOUSE; WILD TYPE;

ALPHA-SYNUCLEIN; ANIMALS; BLOTTING, WESTERN; CHLORIDES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; DOPAMINE; HUMANS; IMMUNOHISTOCHEMISTRY; MANGANESE COMPOUNDS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOTOR ACTIVITY; NERVE DEGENERATION; PARKINSONIAN DISORDERS; SYNAPTIC TRANSMISSION;

EID: 79953200440     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2011.02.017     Document Type: Article

References (75)

1. Abeliovich A., Schmitz Y., Farinas I., Choi-Lundberg D., Ho W.H., Castillo P.E., Shinsky N., Verdugo J.M., Armanini M., Ryan A., Hynes M., Phillips H., Sulzer D., Rosenthal A. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000, 25:239-252.
2. Alerte T.N., Akinfolarin A.A., Friedrich E.E., Mader S.A., Hong C.S., Perez R.G. Alpha-synuclein aggregation alters tyrosine hydroxylase phosphorylation and immunoreactivity: lessons from viral transduction of knockout mice. Neurosci Lett 2008, 435:24-29.
3. Andre C., Truong T.T., Robert J.F., Guillaume Y.C. Effect of metals on herbicides-alpha-synuclein association: a possible factor in neurodegenerative disease studied by capillary electrophoresis. Electrophoresis 2005, 26:3256-3264.
4. Aschner M., Erikson K.M., Dorman D.C. Manganese dosimetry: species differences and implications for neurotoxicity. Crit Rev Toxicol 2005, 35:1-32.
5. Bachmanov A.A., Reed D.R., Beauchamp G.K., Tordoff M.G. Food intake, water intake, and drinking spout side preference of 28 mouse strains. Behav Genet 2002, 32:435-443.
6. Bonilla E. Increased GABA content in caudate nucleus of rats after chronic manganese chloride administration. J Neurochem 1978, 31:551-552.
7. Bonilla E., Arrieta A., Castro F., Davila J.O., Quiroz I. Manganese toxicity: free amino acids in the striatum and olfactory bulb of the mouse. Invest Clin 1994, 35:175-181.
8. Brouillet E.P., Shinobu L., McGarvey U., Hochberg F., Beal M.F. Manganese injection into the rat striatum produces excitotoxic lesions by impairing energy metabolism. Exp Neurol 1993, 120:89-94.
9. Chandra S., Gallardo G., Fernandez-Chacon R., Schluter O.M., Sudhof T.C. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 2005, 123:383-396.
10. Chandra S.V., Shukla G.S., Saxena D.K. Manganese-induced behavioral dysfunction and its neurochemical mechanism in growing mice. J Neurochem 1979, 33:1217-1221.
11. Chandra S.V., Shukla G.S., Srivastava R.S., Gupta S.K. Combined effect of metals on biogenic amines and their distribution in the brain of mice. Arch Environ Contam Toxicol 1980, 9:79-85.
12. Chartier-Harlin M.C., Kachergus J., Roumier C., Mouroux V., Douay X., Lincoln S., Levecque C., Larvor L., Andrieux J., Hulihan M., Waucquier N., Defebvre L., Amouyel P., Farrer M., Destee A. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004, 364:1167-1169.
13. Couper J. On the effects of black oxide of manganese when inhaled into the lungs. Br Ann Med Pharmacol 1837, 1:41-42.
14. Deng Y., Xu Z., Xu B., Tian Y., Xin X., Deng X., Gao J. The protective effect of riluzole on manganese caused disruption of glutamate-glutamine cycle in rats. Brain Res 2009, 1289:106-117.
15. Ehringer H., Hornykiewicz O. Verteilung von noradrenalin und dopamine (3-hydroxytyramin) im gehirn des menschen und ihr verhalten bei erkrankungen des extrapyramidalen systems. Klin Wochenschrift 1960, 38:1238-1239.
16. Faherty C.J., Raviie S.K., Herasimtschuk A., Smeyne R.J. Environmental enrichment in adulthood eliminates neuronal death in experimental parkinsonism. Brain Res Mol Brain Res 2005, 134:170-179.
17. Farrer M., Kachergus J., Forno L., Lincoln S., Wang D.S., Hulihan M., Maraganore D., Gwinn-Hardy K., Wszolek Z., Dickson D., Langston J.W. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol 2004, 55:174-179.
18. Finkelstein M.M., Jerrett M. A study of the relationships between Parkinson's disease and markers of traffic-derived and environmental manganese air pollution in two Canadian cities. Environ Res 2007, 104:420-432.
19. Fitsanakis V.A., Au C., Erikson K.M., Aschner M. The effects of manganese on glutamate, dopamine and gamma-aminobutyric acid regulation. Neurochem Int 2006, 48:426-433.
20. Fleming S.M., Salcedo J., Hutson C.B., Rockenstein E., Masliah E., Levine M.S., Chesselet M.F. Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype alpha-synuclein. Neuroscience 2006, 142:1245-1253.
21. Gianutsos G., Murray M.T. Alterations in brain dopamine and GABA following inorganic or organic manganese administration. Neurotoxicology 1982, 3:75-81.
22. Giasson B.I., Duda J.E., Quinn S.M., Zhang B., Trojanowski J.Q., Lee V.M.Y. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 2002, 34:521-533.
23. Gitler A.D., Chesi A., Geddie M.L., Strathearn K.E., Hamamichi S., Hill K.J., Caldwell K.A., Caldwell G.A., Cooper A.A., Rochet J.C., Lindquist S. Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat Genet 2009, 41:308-315.
24. Gorell J.M., Peterson E.L., Rybicki B.A., Johnson C.C. Multiple risk factors for Parkinson's disease. J Neurol Sci 2004, 217:169-174.
25. Guilarte T.R., Chen M.K., McGlothan J.L., Verina T., Wong D.F., Zhou Y., Alexander M., Rohde C.A., Syversen T., Decamp E., Koser A.J., Fritz S., Gonczi H., Anderson D.W., Schneider J.S. Nigrostriatal dopamine system dysfunction and subtle motor deficits in manganese-exposed non-human primates. Exp Neurol 2006, 202:381-390.
26. Herrera-Marschitz M., Goiny M., You Z.B., Meana J.J., Engidawork E., Chen Y., Rodriguez-Puertas R., Broberger C., Andersson K., Terenius L., Hokfelt T., Ungerstedt U. Release of endogenous excitatory amino acids in the neostriatum of the rat under physiological and pharmacologically-induced conditions. Amino Acids 1998, 14:197-203.
27. Hinzen D., Hornykiewicz O., Kobinger W., Pichler L., Pifl C., Schingnitz G. The dopamine autoreceptor agonist B-HT 920 stimulates denervated postsynaptic brain dopamine receptors in rodent and primate models of Parkinson's disease: a novel approach to treatment. Eur J Pharmacol 1986, 131:75-86.
28. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979, 6:65-70.
29. Hortnagl H., Berger M.L., Sperk G., Pifl C. Regional heterogeneity in the distribution of neurotransmitter markers in the rat hippocampus. Neuroscience 1991, 45:261-272.
30. Ibánez P., Bonnet A.M., Débarges B., Lohmann E., Tison F., Pollak P., Agid Y., Dürr A., Brice P.A. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 2004, 364:1169-1171.
31. Ikeda M., Kawarabayashi T., Harigaya Y., Sasaki A., Yamada S., Matsubara E., Murakami T., Tanaka Y., Kurata T., Wuhua X., Ueda K., Kuribara H., Ikarashi Y., Nakazato Y., Okamoto K., Abe K., Shoji M. Motor impairment and aberrant production of neurochemicals in human alpha-synuclein A30P+A53T transgenic mice with alpha-synuclein pathology. Brain Res 2009, 1250:232-241.
32. Kahle P.J., Neumann M., Ozmen L., Muller V., Jacobsen H., Schindzielorz A., Okochi M., Leimer U., van der Putten H., Probst A., Kremmer E., Kretzschmar H.A., Haass C. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain. J Neurosci 2000, 20:6365-6373.
33. Kapur S., Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996, 153:466-476.
34. Komura J., Sakamoto M. Effects of manganese forms on biogenic amines in the brain and behavioral alterations in the mouse: long-term oral administration of several manganese compounds. Environ Res 1992, 57:34-44.
35. Krüger R., Kuhn W., Müller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J.T., Schöls L., Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998, 18:106-108.
36. Larsen K.E., Schmitz Y., Troyer M.D., Mosharov E., Dietrich P., Quazi A.Z., Savalle M., Nemani V., Chaudhry F.A., Edwards R.H., Stefanis L., Sulzer D. Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J Neurosci 2006, 26:11915-11922.
37. Li Y., Sun L., Cai T., Zhang Y., Lv S., Wang Y., Ye L. Alpha-synuclein overexpression during manganese-induced apoptosis in SH-SY5Y neuroblastoma cells. Brain Res Bull 2010, 81:428-433.
38. Lipe G.W., Duhart H., Newport G.D., Slikker W., Ali S.F. Effect of manganese on the concentration of amino acids in different regions of the rat brain. J Environ Sci Health B 1999, 34:119-132.
39. Liu X., Sullivan K.A., Madl J.E., Legare M., Tjalkens R.B. Manganese-induced neurotoxicity: the role of astroglial-derived nitric oxide in striatal interneuron degeneration. Toxicol Sci 2006, 91:521-531.
40. Madine J., Hughes E., Doig A.J., Middleton D.A. The effects of alpha-synuclein on phospholipid vesicle integrity: a study using 31P NMR and electron microscopy. Mol Membr Biol 2008, 25:518-527.
41. Maskri L., Zhu X., Fritzen S., Kühn K., Ullmer C., Engels P., Andriske M., Stichel C.C., Lübbert H. Influence of different promoters on the expression pattern of mutated human alpha-synuclein in transgenic mice. Neurodegener Dis 2004, 1:255-265.
42. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A., Mucke L. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 2000, 287:1265-1269.
43. Matsumine H., Yamamura Y., Hattori N., Kobayashi T., Kitada T., Yoritaka A., Mizuno Y. A microdeletion of D6S305 in a family of autosomal recessive juvenile parkinsonism (PARK2). Genomics 1998, 49:143-146.
44. Matsuoka Y., Vila M., Lincoln S., McCormack A., Picciano M., LaFrancois J., Yu X., Dickson D., Langston W.J., McGowan E., Farrer M., Hardy J., Duff K., Przedborski S., Di Monte D.A. Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol Dis 2001, 8:535-539.
45. Nelson E., Liang C., Sinton C.M., German D. Midbrain dopaminergic neurons in the mouse: computer-assisted mapping. J Comp Neurol 1996, 369:361-371.
46. Olanow C.W. Manganese-induced parkinsonism and Parkinson's disease. Ann N Y Acad Sci 2010, 1012:209-223.
47. Ordonez-Librado J.L., Anaya-Martinez V., Gutierrez-Valdez A.L., Montiel-Flores E., Corona D.R., Martinez-Fong D., Avila-Costa M.R. l-DOPA treatment reverses the motor alterations induced by manganese exposure as a Parkinson disease experimental model. Neurosci Lett 2010, 471:79-82.
48. Perez R.G., Waymire J.C., Lin E., Liu J.J., Guo F., Zigmond M.J. A role for alpha-synuclein in the regulation of dopamine biosynthesis. J Neurosci 2002, 22:3090-3099.
49. Pettersson E., Herrera-Marschitz M., Rodriguez-Puertas R., Xu Z.Q., You Z.B., Hughes J., Elde R.P., Ungerstedt U., Hokfelt T. Evidence for aspartate-immunoreactive neurons in the neostriatum of the rat: modulation by the mesencephalic dopamine pathway via D1-subtype of receptor. Neuroscience 1996, 74:51-66.
50. Pifl C., Giros B., Caron M.G. Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium. J Neurosci 1993, 13:4246-4253.
51. Pifl C., Hornykiewicz O. Postsynaptic dopamine agonist properties of B-HT 920 as revealed by concomitant D-1 receptor stimulation. Eur J Pharmacol 1988, 146:189-191.
52. Pifl C., Khorchide M., Kattinger A., Reither H., Hardy J., Hornykiewicz O. Alpha-synuclein selectively increases manganese-induced viability loss in SK-N-MC neuroblastoma cells expressing the human dopamine transporter. Neurosci Lett 2004, 354:34-37.
53. Pifl C., Schingnitz G., Hornykiewicz O. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey. Neuroscience 1991, 44:591-605.
54. Pifl C., Wolf A., Rebernik P., Reither H., Berger M.L. Zinc regulates the dopamine transporter in a membrane potential and chloride dependent manner. Neuropharmacology 2009, 56:530-540.
55. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
56. Powers K.M., Smith-Weller T., Franklin G.M., Longstreth W.T., Swanson P.D., Checkoway H. Parkinson's disease risks associated with dietary iron, manganese, and other nutrient intakes. Neurology 2003, 60:1761-1766.
57. Racette B.A., McGee-Minnich L., Moerlein S.M., Mink J.W., Videen T.O., Perlmutter J.S. Welding-related parkinsonism: clinical features, treatment, and pathophysiology. Neurology 2001, 56:8-13.
58. Racette B.A.M., Tabbal S.D.M., Jennings D.M., Good L.B., Perlmutter J.S.M., Evanoff B.M. Prevalence of parkinsonism and relationship to exposure in a large sample of Alabama welders. Neurology 2005, 64:230-235.
59. Ramirez A., Heimbach A., Grundemann J., Stiller B., Hampshire D., Cid L.P., Goebel I., Mubaidin A.F., Wriekat A.L., Roeper J., Al-Din A., Hillmer A.M., Karsak M., Liss B., Woods C.G., Behrens M.I., Kubisch C. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 2006, 38:1184-1191.
60. Richfield E.K., Thiruchelvam M.J., Cory-Slechta D.A., Wuertzer C., Gainetdinov R.R., Caron M.G., Di Monte D.A., Federoff H.J. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Exp Neurol 2002, 175:35-48.
61. Sampathu D.M., Giasson B.I., Pawlyk A.C., Trojanowski J.Q., Lee V.M.Y. Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies. Am J Pathol 2003, 163:91-100.
62. Settivari R., Levora J., Nass R. The divalent metal transporter homologues SMF-1/2 mediate dopamine neuron sensitivity in Caenorhabditis elegans models of manganism and parkinson disease. J Biol Chem 2009, 284:35758-35768.
63. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., Lincoln S., Crawley A., Hanson M., Maraganore D., Adler C., Cookson M.R., Muenter M., Baptista M., Miller D., Blancato J., Hardy J., Gwinn-Hardy K. Alpha-synuclein locus triplication causes Parkinson's disease. Science 2003, 302:841.
64. Soares-da-Silva P., Garrett M.C. A kinetic study of the rate of formation of dopamine, 3,4- dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in the brain of the rat: implications for the origin of DOPAC. Neuropharmacology 1990, 29:869-874.
65. Spiegel H., Sager M., Oberforster M., Mechtler K., Stuger H.P., Baumgarten A. Nutritionally relevant elements in staple foods: influence of arable site versus choice of variety. Environ Geochem Health 2009, 31:549-560.
66. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
67. Thiruchelvam M.J., Powers J.M., Cory-Slechta D.A., Richfield E.K. Risk factors for dopaminergic neuron loss in human alpha-synuclein transgenic mice. Eur J Neurosci 2004, 19:845-854.
68. Uversky V.N., Li J., Fink A.L. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J Biol Chem 2001, 276:44284-44296.
69. van der Putten H., Wiederhold K.H., Probst A., Barbieri S., Mistl C., Danner S., Kauffmann S., Hofele K., Spooren W.P.J.M., Ruegg M.A., Lin S., Caroni P., Sommer B., Tolnay M., Bilbe G. Neuropathology in mice expressing human alpha-synuclein. J Neurosci 2000, 20:6021-6029.
70. van Duijn C.M., Dekker M.C.J., Bonifati V., Galjaard R.J., Houwing-Duistermaat J.J., Snijders P.J.L.M., Testers L., Breedveld G.J., Horstink M., Sandkuijl L.A., van Swieten J.C., Oostra B.A., Heutink P. PARK7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. Am J Hum Genet 2001, 69:629-634.
71. Vidal L., Alfonso M., Campos F., Faro L.R., Cervantes R.C., Duran R. Effects of manganese on extracellular levels of dopamine in rat striatum: an analysis in vivo by brain microdialysis. Neurochem Res 2005, 30:1147-1154.
72. Wakamatsu M., Ishii A., Iwata S., Sakagami J., Ukai Y., Ono M., Kanbe D., Muramatsu S., Kobayashi K., Iwatsubo T., Yoshimoto M. Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice. Neurobiol Aging 2008, 29:574-585.
73. Yavich L., Tanila H., Vepsalainen S., Jakala P. Role of alpha-synuclein in presynaptic dopamine recruitment. J Neurosci 2004, 24:11165-11170.
74. Zarranz J.J., Alegre J., Gomez-Esteban J.C., Lezcano E., Ros R., Ampuero I., Vidal L., Hoenicka J., Rodriguez O., Atares B., Llorens V., Gomez T.E., del Ser T., Munoz D.G., de Yebenes J.G. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004, 55:164-173.
75. Zheng W., Ren S., Graziano J.H. Manganese inhibits mitochondrial aconitase: a mechanism of manganese neurotoxicity. Brain Res 1998, 799:334-342.